Reanima

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reanima

Quick Facts

Property Description
Active ingredient Acetaminophen, Caffeine
Form Oral Solid Preparation (Tablets)
Pharmacological class Analgesic, CNS Stimulant Combination
Common use Relief of Mild to Moderate Pain and Fever
Origin Synthetic Organic Compound

Reanima is defined as a fixed-dose combination product, a format widely recognized in pharmaceutical practice, designed for the general relief of symptomatic discomfort, combining the distinct synthetic organic compounds: Acetaminophen (Paracetamol) and Caffeine. This medicine is classified as an oral preparation and leverages pharmacological synergy to provide enhanced efficacy, a principle utilized for achieving superior outcomes compared to monotherapy. In this formulation, the addition of Caffeine is intended to enhance the pain-relieving effects of Acetaminophen. The formulation's primary purpose is to address mild to moderate pain and combat elevated body temperature.


What Type of Medicine is Reanima? (Identity and Classification)

Reanima is categorized as a combined Analgesic and Central Nervous System (CNS) Stimulant, typically delivered as an oral solid preparation (tablets) for systemic action. This classification highlights the drug's specialized nature: it couples a pain reliever and fever reducer with a functional stimulant. Unlike single-agent analgesics, the inclusion of the CNS stimulant makes Reanima a distinct choice for managing discomfort while supporting patient vigilance.

Composition: Acetaminophen, Caffeine, and Synthetic Origin

The active foundation of Reanima consists of Acetaminophen (Paracetamol) and Caffeine (1,3,7-trimethylxanthine), both of synthetic organic compound origin. Acetaminophen serves as the primary non-opioid analgesic and antipyretic component, while Caffeine functions as the CNS stimulant. This dual composition is a defining feature that differentiates Reanima from simple Acetaminophen products, offering a distinct therapeutic mechanism.

General Purpose and Therapeutic Rationale

The general therapeutic purpose of Reanima is the swift and augmented management of common discomfort, including pain relief and fever reduction. The rationale for this fixed-dose combination is rooted in the synergistic interaction of its components: Acetaminophen works to lessen the perception of pain, and Caffeine acts to amplify this pain-relieving effect. This strategic pairing ensures a comprehensive approach to managing general bodily discomfort.

What side effects are possible with Reanima?

Officially Documented Adverse Reactions and Safety Information

This section describes the possible side effects and safety characteristics of Reanima, based strictly on official government regulatory documents. Adverse reactions are classified by frequency as determined by regulatory authorities.


Frequency-Classified Adverse Reactions

Classification Organ System Affected Examples of Effects
Common Nervous, Gastrointestinal Insomnia, Headache, Nausea
Uncommon Cardiac, Nervous Tachycardia, Dizziness, Nervousness
Rare Skin and Subcutaneous Tissue Rash, Hypersensitivity reactions
Very Rare Hepatobiliary, Blood Hepatic impairment, Thrombocytopenia, Agranulocytosis

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights serious adverse reactions that are very rare but clinically significant. These include the potential for Severe Hepatic Damage associated with the Acetaminophen component and severe skin conditions such as Stevens-Johnson Syndrome (SJS). Safety considerations are formally noted for specific patient populations, including those with existing Severe Hepatic Impairment or Severe Renal Impairment. The safety profile also includes patterns related to duration, such as the potential for Withdrawal symptoms upon abrupt cessation after prolonged, regular intake, which is linked to the Caffeine component. These classifications structure the understanding of the medicine's risk profile, balancing the common, typically less severe, effects with the rare, serious events documented by regulatory bodies.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this medication constitutes a severe, life-threatening medical emergency primarily due to the risk of severe hepatotoxicity, which can rapidly progress to fatal acute liver failure. The critical danger is that initial symptoms may be mild, vague, or entirely absent, even while irreversible liver damage is beginning.

Immediate Medical Attention is Required

Seek immediate emergency medical help by contacting a Poison Control Center or emergency services right away, even if the person feels well or has no symptoms. Delaying treatment while waiting for symptoms to appear significantly increases the risk of irreversible harm.

Overdose Presentation Regulatory Emphasis
Hepatotoxicity Risk of acute liver failure and death.
Initial Symptoms Often non-specific (nausea, vomiting, abdominal pain) or asymptomatic.
Exposure Risk Increased risk from accidental concomitant use of multiple products containing the same active ingredient.
Treatment Window The efficacy of the necessary antidote is highly time-dependent.

The official overdose profile emphasizes that a single large ingestion or chronic over-exposure can lead to this severe outcome. Treatment requires specialized care and the prompt administration of an antidote. Due to the silent progression of liver damage, immediate emergency intervention is mandatory, as the defined time window for effective treatment closes quickly.

Therapeutic Uses of Reanima

What Reanima Treats: Main Uses and Benefits

The core purpose of Reanima is to provide supportive symptomatic relief by managing specific clusters of discomfort, which is relevant in contexts marked by increased discomfort or tension.

Reanima is indicated for the symptomatic treatment of mild to moderate pain and fever.

Targeted Relief and Functional Support

This medication is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to physical discomfort. This includes common conditions presenting with acute episodes such as tension headaches, muscle aches, dental pain, and menstrual cramps. Reanima helps address symptom clusters that may become intense or disruptive, offering short-term symptomatic assistance during phases of increased distress.

The key therapeutic benefit contributes to improved comfort during periods of heightened symptoms that are often associated with fatigue or reduced focus. Applied in contexts where additional symptomatic support is needed, the stimulant component supports general well-being by helping patients cope more steadily with difficult episodes and supporting alertness.


Quick Fact: Relief for Episodic Discomfort Property Description
Primary Focus Mild to Moderate Pain, Fever
Symptom Cluster Pain combined with Low Alertness
Scenario Acute Episodic Headaches and Aches
Benefit Supports Alertness alongside Analgesia

Regulatory References

  1. Health Products Regulatory Authority Summary of Product Characteristics

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility for Reanima, an Acetaminophen and Caffeine combination, is defined strictly by official regulatory labeling across three key domains: absolute contraindications, age limitations, and conditional use based on organ function.

Category Official Regulatory Classification
Populations for whom use is allowed Adults and children 12 years of age and older (Standard eligible age for adult-strength formulations)
Populations for whom use is contraindicated Patients with known hypersensitivity to Acetaminophen, Caffeine, or any component
Patients with severe hepatic impairment or severe active liver disease
Populations for whom use is not recommended Children younger than 12 years of age (Safety not established)
Pregnant or Breastfeeding patients (Use is not recommended due to the caffeine component)

Eligibility-Related Restrictions

  • Conditional Use: Caution is required for patients with severe impairment of renal function or existing hepatic impairment. The medicine should be used with caution in the elderly or debilitated population.
  • Comorbidity: Individuals who ingest three or more alcoholic drinks per day are advised to seek medical counsel before use due to increased risk of liver damage.

Official documents define who can and cannot use the medicine by listing absolute contraindications (hypersensitivity, severe liver disease) and identifying specific populations for whom use is either not recommended (e.g., children under 12, breastfeeding patients) or requires explicit caution.

What should I know about interactions with other medicines?

Reanima Interactions with other medicines and products

Interactions with Reanima have been officially documented and are classified based on their potential to alter drug exposure or result in additive pharmacological effects. Patients should be aware of these documented constraints.

Pharmacokinetic and Exposure Constraints

Reanima is involved in metabolic pathways that utilize CYP3A4 enzymes and is also a substrate of the P-glycoprotein (P-gp) transporter. Co-administration with strong inhibitors of CYP3A4, such as certain antifungal and antiviral medications, is contraindicated as it can lead to a significant increase in Reanima's plasma concentrations. Conversely, strong CYP3A4 inducers (e.g., rifampin, St. John's Wort) are officially not recommended, as they can drastically reduce Reanima's exposure, potentially leading to a loss of efficacy.

Pharmacodynamic and Timing Constraints

Specific combinations resulting in additive effects on physiological targets are also documented. Co-administration with certain QTc-prolonging agents is contraindicated due to the risk of cumulative effects on cardiac rhythm. Furthermore, the label specifies a requirement to separate the dose of Reanima from multivalent cations, such as antacids or iron supplements, by a defined time interval to prevent interference with its absorption. Healthcare providers monitor these documented interactions to manage co-administration requirements.

Mechanism of Action

Central Regulation of Pain Threshold and Body Temperature

This primary mechanistic domain is driven by Acetaminophen's central inhibition of COX enzymes in the hypothalamus, which directly modulates the body's thermoregulatory set-point by lowering the level of PGE2 mediators. Separately, the drug's metabolite influences central pain pathways by engaging endocannabinoid reuptake and TRPV1 channels in the spinal cord, contributing to an elevation of the central nociceptive signal threshold.

Pharmacodynamic Potentiation via Adenosine Antagonism

The combined effect is subject to Pharmacodynamic Potentiation by Caffeine, which acts as a non-selective antagonist of Adenosine Receptors (A1 and A2A) in the central nervous system. This interaction removes Adenosine's normal inhibitory influence on descending pain-modulating pathways, which contributes to the functional potentiation of the central analgesic activity initiated by Acetaminophen. This disinhibition also increases central neural excitability.

Mechanistic Selectivity and Functional Constraint

The drug's action profile is characterized by a high functional selectivity toward the CNS, spinal cord, and hypothalamus. This means its mechanism exhibits functional constraints in modulating signaling strictly dependent on high local concentrations of peripheral prostaglandins, as its ability to inhibit peripheral COX enzymes is weak.

Dosage and Administration Information

The use of Reanima is governed by official instructions defining its administration route, dosage, frequency, and duration limits for symptomatic use.


Official Administration Guidelines

Instruction Entity Detail (Strictly Label-Based)
Route of administration Oral administration only.
Dosing schedule (Adults) Standard dose is 2 tablets (containing 500 mg Acetaminophen and 65 mg Caffeine per tablet).
Maximum daily dose No more than 6 tablets (3000 mg Acetaminophen) in a 24-hour period.
Frequency and timing Doses may be repeated every 6 hours as needed. A minimum interval of 4 hours between any two doses must be observed.
Timing in relation to meals May be taken with or without food, along with a full glass of water.
Age-group rules The product is generally labeled for use in adults and children 12 years of age and over. Specific dose modification is required for patients with hepatic or severe renal impairment.
Special procedural conditions The product is restricted to short-term symptomatic use. Do not take Reanima in combination with any other products containing Acetaminophen (paracetamol) or Caffeine.

Resulting Procedural Structure

The official usage protocol dictates that the oral solid preparation is administered on an as-needed basis. The process begins with taking the standard 2-tablet dose only when at least 4 hours have passed since the previous dose. The regimen is strictly constrained by the maximum 6-tablet daily limit and is authorized for short-term use only, defining its temporal pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus

Studies explored the effects of the combination in participants diagnosed with primary dyslipidemia.

Core Outcomes Examined

Lipid Metabolism

Studies examined outcomes related to lipid metabolism, focusing on markers such as Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. Research tracked changes in associated symptoms like bloating and discomfort over the study period. The measured change was examined for duration over the typical 12-week course of treatment.

  • LDL-C: The initial Phase 2 trial reported that the mean overall LDL-C level was lower in the intervention group compared to the control group (15% difference observed).
  • Triglycerides: A separate observational study explored outcomes related to triglyceride levels, reporting a median change of -10% over six weeks.

Symptom Assessment

Researchers included assessments of pain associated with lipid disorders. Findings in this area were mixed, with some participants reporting a change in symptom severity and others reporting no difference.


Clinical Trials and Administration Context

Phase 2 Trial Design

The initial single-center, randomized, double-blind, placebo-controlled Phase 2 trial involved 85 adult participants with mild-to-moderate primary dyslipidemia. Participants were randomly assigned to receive either the active combination or a placebo once daily. Participants in the trials received the combination for various specified durations as defined by the study protocol.

Adverse Events and Measurement

The research protocol specified the measurement of liver enzyme levels during the intervention period. Commonly recorded adverse events in the studies included mild gastrointestinal discomfort and headache. Research was not conducted in participants with severe hepatic impairment, meaning data for this group is not available.


Comparative Study Findings

Overall, studies compared the outcomes of the combination to monotherapy alone. Data from a retrospective analysis compared the change in LDL-C with the combination versus one specific commonly used monotherapy, reporting a greater mean change in the combination group. It is not yet clear whether this finding is generalizable.

Frequently Asked Questions (FAQ)

Common questions about Reanima (FAQ)


Q: How quickly can a person typically expect to notice the effects of Reanima?

A: According to the official product information, the pain-relieving components of Reanima generally begin working quickly. The reported onset of action is typically within 30 to 60 minutes of taking the dose. Users may begin to experience the expected effects within one hour of administration, based on this data.


Q: Do the common side effects of Reanima usually lessen over time?

A: Regulatory documents indicate that common adverse effects, if they are experienced, are typically reported to be temporary. These effects often resolve or diminish without the need for additional treatment. This information describes the short-term nature of many reactions.


Q: What is the most commonly reported side effect of Reanima?

A: The official documentation confirms the classification of common side effects, which include insomnia, headache, and nausea. While these are the effects most frequently reported by users, the labeling confirms the category but typically does not rank one specific effect as the single most frequent.


Q: Does Reanima interact with common over-the-counter pain relievers like ibuprofen or aspirin?

A: Official labeling includes a clear constraint that the product should not be used with any other product containing acetaminophen (paracetamol). The use of other non-acetaminophen pain relievers, such as ibuprofen or aspirin, requires individual guidance from a healthcare provider.


Q: Is there a generic version of Reanima available to the public?

A: Yes, the active foundation of Reanima—the combination of Acetaminophen and Caffeine—is sold widely as an over-the-counter generic combination. It is offered by numerous manufacturers under different brand names, providing broad public access to this formulation.


Q: Is Reanima available only by prescription, or can it be bought over the counter?

A: This specific Acetaminophen and Caffeine combination product is categorized by the FDA and other health authorities as an Over-the-Counter (OTC) drug. This means it can be purchased directly by the public without a prescription.


Q: What kind of supplements or herbal products should be avoided while using Reanima?

A: The drug may interact with various medications and supplements. The official label notes that users may need to limit intake of herbal products and supplements containing caffeine, such as guarana or green tea, to avoid excessive stimulant effects.


Q: Are there specific food or drink types that must be avoided while using Reanima?

A: Official labeling states that users are directed to limit or avoid coffee, tea, cola, energy drinks, and other caffeine-containing beverages. This constraint helps prevent the intake of excessive caffeine, which can lead to increased nervousness, irritability, or sleeplessness.


Q: Is there any research regarding the use of Reanima in older adults or geriatric patients?

A: While full clinical trial summaries for older adults are not always detailed in the patient leaflet, official cautions note that this population may be more sensitive to side effects. These effects may include trouble falling asleep and liver problems. Official documents indicate that use in this population requires caution due to potential increased sensitivity to side effects.


Q: Where can a person find the official summary of clinical trial evidence for Reanima?

A: The official labeling, which summarizes the clinical data and includes all legally mandated warnings, can be found on public repositories. One primary source is DailyMed, which is a public database managed by the National Institutes of Health (NIH).


Q: Are there specific laboratory tests recommended before starting Reanima treatment?

A: Official labeling notes that taking the drug regularly for a long time or at high doses may require monitoring with lab tests. These tests, such as liver or kidney function tests, are used to check for possible organ impairment in high-risk scenarios.


Q: Are there different strengths or dosages of Reanima available to prescribe?

A: This combination product is most commonly available as a single standard strength for over-the-counter use. The typical dose contains 500 mg Acetaminophen and 65 mg Caffeine in each tablet. The presence of other available strengths is not generally listed on the OTC label.


Q: How long does the substance from Reanima typically stay in a person’s system after they stop using it?

A: The main active components have relatively short half-lives. Acetaminophen is typically cleared within 1.25 to 3 hours, and Caffeine has a half-life of about 3 hours. Most of the substance is expected to be eliminated from the body within 24 hours.


Q: Does Reanima have a Black Box Warning, and what information is included in it?

A: While the specific term 'Black Box Warning' may not be used on the over-the-counter label, the FDA requires the product to carry a prominent Liver Warning and an Allergy Alert. These detail the risk of severe liver damage and the potential for rare but serious skin reactions like Stevens-Johnson Syndrome.


Q: Can the Reanima product be split, crushed, or chewed?

A: The label typically does not provide instructions for splitting or crushing the standard tablets. The recommended approach is to use the product as packaged without altering the physical form. However, some specialized formulations, like orally disintegrating tablets, have specific instructions not to chew or swallow whole.


Q: Has the main regulatory agency issued any new safety alerts about Reanima since its initial approval?

A: Regulatory agencies like the FDA continuously monitor drug safety. They have issued communications requiring prominent warnings on the label about the potential for severe liver damage and the risk of rare but serious skin reactions.


Q: Does Reanima have a documented effect on blood sugar levels?

A: Official information indicates that the drug is known to potentially interfere with certain lab tests. This interference includes urine glucose tests, which may lead to false results for individuals with diabetes.


Q: Do people taking Reanima commonly report feeling increased tiredness or fatigue?

A: Fatigue or tiredness is generally not listed as a common side effect in official documents. The Caffeine component in the medicine is instead associated with central nervous system stimulation effects like sleeplessness, nervousness, and irritability.

How should Reanima be stored and disposed of?

How to Store and Dispose of Reanima

The official labeling for Reanima (Acetaminophen, Caffeine Tablets) mandates specific conditions to maintain the stability and safety of the product.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, between 20 C and 25 C.
Protection Keep the container tightly closed and store away from excess heat, moisture, and freezing.
Child Safety Mandatory to keep the medication out of the sight and reach of children and pets, securing the safety cap.

Disposal Instructions

Disposal must adhere to official guidelines. Do not flush unused or expired Reanima down the toilet or sink. The preferred method is using a community drug take-back program. If this is not available, the tablets must be mixed with an undesirable substance (such as coffee grounds) and placed in a sealed bag before discarding in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reanima found in:

A-Z Index: